top of page

Understanding Spravato: A Breakthrough Treatment for Depression

At Star Behavioral Health, we are committed to providing innovative and effective treatments for mental health conditions. One such groundbreaking treatment is Spravato (esketamine) nasal spray, which offers new hope for those struggling with treatment-resistant depression. In this blog post, we will explore what Spravato is, how it works, and what patients can expect from this cutting-edge therapy.

What is Spravato?

Spravato is an FDA-approved nasal spray specifically designed to treat adults with treatment-resistant depression. Unlike traditional antidepressants, which typically target serotonin, norepinephrine, and dopamine pathways, Spravato works differently. It targets the NMDA receptor in the brain, a part of the glutamate system, which plays a crucial role in mood regulation.

How Does Spravato Work?

Spravato is administered as a nasal spray in a clinical setting under the supervision of a healthcare professional. Here’s how the treatment process generally works:

  1. Initial Phase: Spravato is administered twice a week for the first four weeks. Patients are monitored for at least two hours after each session to ensure safety and manage any immediate side effects.

  2. Maintenance Phase: After the initial phase, the frequency of treatments is gradually reduced. This phase typically involves once-weekly sessions, which may eventually be reduced to once every two weeks, depending on the patient's response and needs.

Spravato is used in conjunction with an oral antidepressant to enhance its effectiveness and provide comprehensive treatment for depression.

Benefits of Spravato

  1. Rapid Relief: Unlike traditional antidepressants that may take weeks to show effects, many patients experience significant improvement in their symptoms within hours to days after starting Spravato treatment.

  2. Effective for Treatment-Resistant Depression: Spravato has shown substantial efficacy in patients who have not responded to other antidepressant treatments, providing a new option for those who have struggled with finding effective relief.

  3. Non-Invasive and Convenient: As a nasal spray, Spravato is a non-invasive treatment that can be easily administered in a clinical setting without the need for lengthy hospital stays or complicated procedures.

What to Expect During Treatment

Patients receiving Spravato at Star Behavioral Health can expect a supportive and professional environment. Here’s a brief overview of the treatment experience:

  • Pre-Treatment: Before starting Spravato, a thorough evaluation is conducted to ensure it is the right treatment for you. This includes discussing your medical history, current medications, and any potential risks or side effects.

  • During Treatment: Each session lasts approximately two hours, including the administration of the nasal spray and the subsequent observation period. During this time, patients are monitored for any adverse effects and provided with a comfortable and supportive environment.

  • Post-Treatment: After the observation period, patients can return home but are advised not to drive or operate heavy machinery until the next day. Follow-up appointments are scheduled to monitor progress and adjust the treatment plan as needed.

Is Spravato Right for You?

Spravato is a promising option for individuals with treatment-resistant depression who have not found relief with other antidepressants. However, it is important to discuss this treatment with your healthcare provider to determine if it is suitable for your specific needs.

At Star Behavioral Health, our experienced team is here to guide you through the process and provide the highest level of care. If you think Spravato might be right for you, contact us today to schedule a consultation and take the first step towards a brighter future.

11 views0 comments

Recent Posts

See All

Spravato Success

Star Behavioral Health has had great success in helping many patients achieve remission from their depression. We have performed over...

Comments


bottom of page